ArticleCureus2026
Treatment of Acute Myeloid Leukemia in Elderly Patients With Azacitidine-Venetoclax Combination in Developing Countries: A Single-Center Experience.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesAcute myeloid leukemia (AML) predominantly affects elderly patients and is associated with a poor prognosis. Therapeutic options remain limited for patients who are ineligible for intensive chemotherapy. Real-world data on the use of azacitidine-venetoclax (AZA-VEN) in North African populations are scarce. This study aimed to assess the effectiveness, composite complete remission rates, and safety profile of AZA-VEN in elderly AML patients treated at a Moroccan center. MATERIALS AND
methodsWe conducted a retrospective study including patients aged ≥60 years who received AZA-VEN between July 2021 and August 2024 at the Military Hospital Ibn Sina in Marrakech. VEN was administered with a ramp-up protocol, combined with AZA and prophylactic voriconazole. Treatment response was assessed after the first cycle using bone marrow aspiration and blood counts. Overall survival (OS) was estimated using Kaplan-Meier curves.
resultsEight patients were included, with a median age of 67 years and a male predominance. Seven patients had comorbidities. Four patients achieved complete remission (CR) after the first cycle, while two showed no response. Four patients experienced relapse or disease progression during follow-up. Grade 3-4 hematologic toxicities were frequent: neutropenia in all eight patients, anemia in seven patients, and thrombocytopenia in seven patients. All patients developed infectious complications. Median follow-up was 17 months, with a median survival of 25 months. Four out of eight patients were alive at two years.
conclusionsOur single-center experience confirms that AZA-VEN is an effective and feasible therapeutic option for elderly AML patients, with a median survival of 25 months. Hematologic and infectious toxicities remain major challenges. In a North African context, limited access to VEN due to its cost can be partially mitigated through dose adjustments with azole antifungals. Further prospective multicenter studies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.